The cytokine/chemokine response in Leishmania/HIV infection and co-infection

S Maksoud, J El Hokayem - Heliyon, 2023 - cell.com
HIV infection progressively weakens the immune system by infecting and destroying cells
involved in host defense. Viral infection symptoms are generated and aggravated as …

Leishmaniasis: immune cells crosstalk in macrophage polarization

FS Almeida, SER Vanderley, FC Comberlang… - Tropical Medicine and …, 2023 - mdpi.com
Leishmaniasis is a complex infectious parasitic disease caused by protozoa of the genus
Leishmania, belonging to a group of neglected tropical diseases. It establishes significant …

Recent advances in the development of adenovirus-vectored vaccines for parasitic infections

C Koger-Pease, DJ Perera, M Ndao - Pharmaceuticals, 2023 - mdpi.com
Vaccines against parasites have lagged centuries behind those against viral and bacterial
infections, despite the devastating morbidity and widespread effects of parasitic diseases …

Next-Generation Leishmanization: Revisiting Molecular Targets for Selecting Genetically Engineered Live-Attenuated Leishmania

POL Moreira, PM Nogueira, RL Monte-Neto - Microorganisms, 2023 - mdpi.com
Despite decades of research devoted to finding a vaccine against leishmaniasis, we are still
lacking a safe and effective vaccine for humans. Given this scenario, the search for a new …

Repurposing the antibacterial agents peptide 19-4LF and peptide 19-2.5 for treatment of cutaneous leishmaniasis

R El-Dirany, C Fernández-Rubio, J Peña-Guerrero… - Pharmaceutics, 2022 - mdpi.com
The lack of safe and cost-effective treatments against leishmaniasis highlights the urgent
need to develop improved leishmanicidal agents. Antimicrobial peptides (AMPs) are an …

Immunotherapy for visceral leishmaniasis: A trapeze of balancing counteractive forces

PH Mazire, B Saha, A Roy - International immunopharmacology, 2022 - Elsevier
The protozoan parasite Leishmania donovani, residing and replicating within the cells of the
monocyte-macrophage (mono-mac) lineage, causes visceral leishmaniasis (VL) in humans …

Role of Treg, Breg and other cytokine sets in host protection and immunopathology during human leishmaniasis: Are they potential valuable markers in clinical …

F Divenuto, G Pavia, N Marascio, GS Barreca… - Acta Tropica, 2023 - Elsevier
Leishmaniasis is a vector-borne disease caused by obligate intracellular protozoan
parasites that can infect humans and other mammals. Pro-and anti-inflammatory cytokines …

TLR-2 agonist Pam3CSK4 has no therapeutic effect on visceral leishmaniasis in BALB/c mice and may enhance the pathogenesis of the disease

X Liao, J He, R Wang, J Zhang, S Wei, Y Xiao, Q Zhou… - Immunobiology, 2023 - Elsevier
Most of the existing Leishmania-related research about TLR-2 agonists was focusing on
their role as adjuvants in the vaccine, few studied its therapeutic effect. This paper aims to …

Monitoring cutaneous Leishmaniasis lesions in mice undergoing topical Miltefosine treatment

LF Neira, JC Mantilla, P Escobar - Scientia Pharmaceutica, 2023 - mdpi.com
A study was conducted on BALB/c mice infected with Leishmania (Leishmania)
amazonensis to analyse the effects of 0.5% miltefosine (MTF) hydrogel treatment on …

Chemokines: A key driver for inflammation in protozoan infection

R Chauhan, M Tiwari, A Chaudhary… - International Reviews …, 2024 - Taylor & Francis
Chemokines belong to the group of small proteins within the cytokine family having strong
chemo-attractant properties. In most cases, the strong immuno-modulatory role of …